Market Overview

UPDATE: Stifel Nicolaus Raises PT to $6.51 on Boston Scientific Corporation S-ICD Checks

Share:
Related BSX
Boston Scientific Is 'Riding The Wave Of Business Improvement'
Morgan Stanley Reiterates Overweight, Raises PT On Boston Scientific On Path To 2017
Significant Revenue Gains In Store For Boston Scientific (Seeking Alpha)

Stifel Nicolaus reiterated Boston Scientific Corporation (NYSE: BSX) at Buy and increased the price target from $6.50 to $7.00.

Stifel Nicolaus noted, "Our recent physician checks with U.S. and EU electrophysiologists (EPs) reinforce our thesis that ultimately S-ICDs could represent 10% or more of overall ICD implants over time, if ongoing registry trials continue to suggest comparable performance versus traditional ICDs. We suspect this 10% penetration is greater than generally expected. These checks also reinforced our view that the S-ICD could potentially help re-invigorate BSX's beleaguered ICD franchise (~19% of 2012 estimated sales)."

Boston Scientific Corporation closed at $6.51 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Mar 2015BarclaysMaintainsOverweight
Mar 2015Raymond JamesInitiates Coverage onOutperform
Mar 2015BMO CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...